Reach Separations celebrates 5th birthday with record year
The company’s growth has been driven by export, with a three-fold increase in activity outside of the UK during 2016,
Reach Separations, a UK-based purification specialist, has marked its fifth anniversary with a record year of growth following a surge in demand for its small molecule synthesis capabilities from pharmaceutical companies across Europe.
Reach Separations, which is headquartered at BioCity in Nottingham, has grown by one third since 2015 and is now working with most of the world’s big pharma firms along with many contract research organisations (CROs) that are involved in developing new compounds.
The company’s growth has been driven by export, with a three-fold increase in activity outside of the UK during 2016, and follows significant investment in analytical equipment and purification systems. This has enabled it to increase chromatography capacity to support clients working in drug discovery that require purified materials under tight timescales.
Reach Separations has carved a niche for itself in the purification services space by supporting research chemists and scientists. Over the past 5 years, its team has established itself as one of the most sophisticated and reliable chromatography purification providers in the global contract services market.
The company’s technical group is headed by director and former Separation Science Group Leader at AstraZeneca, Phil Abbott, who has worked in the pharmaceutical industry for around 25 years.
He said: “We are delighted with the progress the company has made since we started. I believe our growth has been fuelled by our reputation to simply deliver a high quality purification and analysis service in a dependable and speedy manner.
“Once we get the opportunity to work with a new chemistry group, they then tend to use us again and again as they know they can rely on our team for a rapid turnaround time on materials they send to our lab for either testing or purification.
“As our capacity and capabilities have extended, it’s opened up new opportunities in new markets, which has led to over 60% of our business now coming from clients outside of the UK.”
To support business growth, Reach Separations has grown to 10 people and is currently recruiting for several new positions to support its expansion plans in 2017.
Phil continued: “We will certainly be on the lookout for talented scientists over the next year that we will train to become highly skilled chromatographers. That’s our commitment to our team.
“We also have plans to make further investment in technology and equipment that will raise the bar even further,” added Phil.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance